Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19
Xuping Xie, Antonio E. Muruato, Xianwen Zhang, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 223

Showing 1-25 of 223 citing articles:

N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2
Matthew McCallum, Anna De Marco, Florian A. Lempp, et al.
Cell (2021) Vol. 184, Iss. 9, pp. 2332-2347.e16
Open Access | Times Cited: 936
Evasion of Type I Interferon by SARS-CoV-2
Hongjie Xia, Zengguo Cao, Xuping Xie, et al.
Cell Reports (2020) Vol. 33, Iss. 1, pp. 108234-108234
Open Access | Times Cited: 931
Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms
M. Alejandra Tortorici, Martina Beltramello, Florian A. Lempp, et al.
Science (2020) Vol. 370, Iss. 6519, pp. 950-957
Open Access | Times Cited: 582
SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape
Tyler N. Starr, Nadine Czudnochowski, Zhuoming Liu, et al.
Nature (2021) Vol. 597, Iss. 7874, pp. 97-102
Open Access | Times Cited: 493
A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation
Antonio E. Muruato, Camila R. Fontes-Garfias, Ping Ren, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 310
Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies
Florian A. Lempp, Leah Soriaga, Martin Montiel-Ruiz, et al.
Nature (2021) Vol. 598, Iss. 7880, pp. 342-347
Closed Access | Times Cited: 293
Broad sarbecovirus neutralization by a human monoclonal antibody
M. Alejandra Tortorici, Nadine Czudnochowski, Tyler N. Starr, et al.
Nature (2021) Vol. 597, Iss. 7874, pp. 103-108
Open Access | Times Cited: 272
Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template
Calvin J. Gordon, Egor P. Tchesnokov, Raymond F. Schinazi, et al.
Journal of Biological Chemistry (2021) Vol. 297, Iss. 1, pp. 100770-100770
Open Access | Times Cited: 258
SARS-CoV-2 tropism, entry, replication, and propagation: Considerations for drug discovery and development
Nicholas Murgolo, Alex G. Therien, Bonnie J. Howell, et al.
PLoS Pathogens (2021) Vol. 17, Iss. 2, pp. e1009225-e1009225
Open Access | Times Cited: 204
Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy
Irfan Ullah, Jérémie Prévost, Mark S. Ladinsky, et al.
Immunity (2021) Vol. 54, Iss. 9, pp. 2143-2158.e15
Open Access | Times Cited: 193
Engineering SARS-CoV-2 using a reverse genetic system
Xuping Xie, Kumari G. Lokugamage, Xianwen Zhang, et al.
Nature Protocols (2021) Vol. 16, Iss. 3, pp. 1761-1784
Open Access | Times Cited: 177
A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection
Guillaume Beaudoin-Bussières, Yaozong Chen, Irfan Ullah, et al.
Cell Reports (2022) Vol. 38, Iss. 7, pp. 110368-110368
Open Access | Times Cited: 114
SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19
Ilaria Vicenti, Maurizio Zazzi, Francesco Saladini
Expert Opinion on Therapeutic Patents (2021) Vol. 31, Iss. 4, pp. 325-337
Open Access | Times Cited: 112
Bidirectional genome-wide CRISPR screens reveal host factors regulating SARS-CoV-2, MERS-CoV and seasonal HCoVs
Antoine Rebendenne, Priyanka Roy, Boris Bonaventure, et al.
Nature Genetics (2022) Vol. 54, Iss. 8, pp. 1090-1102
Open Access | Times Cited: 97
Accelerating antiviral drug discovery: lessons from COVID-19
Annette von Delft, Matthew D. Hall, Ann D. Kwong, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 7, pp. 585-603
Open Access | Times Cited: 94
A live-attenuated SARS-CoV-2 vaccine candidate with accessory protein deletions
Yang Liu, Xianwen Zhang, Jianying Liu, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 76
Fatal Neurodissemination and SARS-CoV-2 Tropism in K18-hACE2 Mice Is Only Partially Dependent on hACE2 Expression
Mariano Carossino, Devin Kenney, Aoife K. O’Connell, et al.
Viruses (2022) Vol. 14, Iss. 3, pp. 535-535
Open Access | Times Cited: 69
Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice
Alexandra Schäfer, David R. Martinez, John J. Won, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 643
Open Access | Times Cited: 67
Development of Highly Potent Noncovalent Inhibitors of SARS-CoV-2 3CLpro
Ningke Hou, Lei Shuai, Lijing Zhang, et al.
ACS Central Science (2023) Vol. 9, Iss. 2, pp. 217-227
Open Access | Times Cited: 60
Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review
Xin Li, Yongcheng Song
European Journal of Medicinal Chemistry (2023) Vol. 260, pp. 115772-115772
Open Access | Times Cited: 51
Integrated multi-omics analyses identify anti-viral host factors and pathways controlling SARS-CoV-2 infection
Jiakai Hou, Yanjun Wei, Jing Zou, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 18
Challenges for Targeting SARS-CoV-2 Proteases as a Therapeutic Strategy for COVID-19
Kas Steuten, Heeyoung Kim, John C. Widen, et al.
ACS Infectious Diseases (2021) Vol. 7, Iss. 6, pp. 1457-1468
Open Access | Times Cited: 90
Overcoming Culture Restriction for SARS-CoV-2 in Human Cells Facilitates the Screening of Compounds Inhibiting Viral Replication
Santseharay Ramírez, Carlota Fernandez-Antunez, Andrea Galli, et al.
Antimicrobial Agents and Chemotherapy (2021) Vol. 65, Iss. 7
Open Access | Times Cited: 77
A trans-complementation system for SARS-CoV-2 recapitulates authentic viral replication without virulence
Xianwen Zhang, Yang Liu, Jianying Liu, et al.
Cell (2021) Vol. 184, Iss. 8, pp. 2229-2238.e13
Open Access | Times Cited: 73
Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays
Chunlong Ma, Haozhou Tan, Juliana Choza, et al.
Acta Pharmaceutica Sinica B (2021) Vol. 12, Iss. 4, pp. 1636-1651
Open Access | Times Cited: 72
Page 1 - Next Page

Scroll to top